Zim Labs

Nagpur, India Founded: 1989 • Age: 37 yrs Listed
Solid and semisolid dosage forms are developed and manufactured.

About Zim Labs

Zim Labs is a publicly listed company based in Nagpur (India) founded in 1989. Solid and semisolid dosage forms are developed and manufactured. Zim Labs has raised $8.2 million across 2 funding rounds from investors including Ashmore. The company has 577 employees. Its website zimlab.in draws about 12 thousand monthly visits. Its Indian entity Zim Laboratories Limited. reported revenue of β‚Ή386 Cr. Zim Labs offers products and services including Oral Thin Films, Pre-Formulation Intermediates, and Finished Formulations. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Inventia Healthcare and Halewood Laboratories; 1 of its 2 listed competitors has raised funding.

Company details

Zim Labs was founded in 1989 and is based in Nagpur, India, within the pharmaceutical sector. Various solid and semisolid dosage forms, such as granules, pellets with sustained, modified, or extended release, taste-masked powders, suspensions, tablets, capsules, and oral thin films, are developed and manufactured. Services provided include drug release modifications, solubility enhancement, and taste masking for pharmaceutical applications.

  • Headquarters Nagpur, India
  • Employees 577
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website zimlab.in
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Zim Laboratories Ltd.
Key Metrics
  • Market Cap
    ₹799 Cr

    ZIMLAB · NSE

  • Share Price
    ₹147.80

    -0.69% today

  • Revenue
    ₹374 Cr

    FY 2025-26 · -1.2% YoY

  • EBITDA
    ₹30.01 Cr

    Margin 8.0%

  • Net Profit
    ₹4.35 Cr

    FY 2025-26 · -63.5% YoY

  • P/E (TTM)
    350.9x

    P/B 2.5x

  • ROE
    1.6%

    ROCE 4.8%

  • Debt / Equity
    0.45

    Interest cover 131.6x

  • Total Equity Funding
    $8.2M (USD)

    in 2 rounds

  • Investors
  • Employee Count
    577

Products & Services of Zim Labs

Zim Labs offers a comprehensive portfolio of products and services, including Oral Thin Films, Pre-Formulation Intermediates, and Finished Formulations.

Oral Thin Films
Finished Formulations

Provides drug delivery films for patient convenience and adherence.

Pre-Formulation Intermediates
Intermediates

Offers granules and pellets for generic product development.

Finished Formulations
Formulations

Supplies tablets and capsules for regulated markets.

Apps and channels of Zim Labs

its YouTube channel ZIM Laboratories has 506 subscribers and 30 videos.

ZIM Laboratories
YouTube 506 subscribers 30 videos Film & Animation
Open channel

Videos from Zim Labs

The most watched videos on Zim Labs's YouTube channel, ZIM Laboratories (506 subscribers). Click a video to play it here.

Zim Laboratories Limited - Oral Thin Film
3.3K views
ZIM Laboratories Limited - Corporate Film
2K views
Dr.Anwar S. Daud, CMD ZIM Laboratories Ltd - Interview with IIFL Securities on NSE Debut
1.4K views
Ziminta - Mint Flavour
1.1K views

More on ZIM Laboratories.

Funding Insights of Zim Labs

Zim Labs has successfully raised a total of $8.2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $8.2M
  • Total Rounds 2
  • First Round $8.2M

    (Jan 2013)

  • Investors Count 1

All 2 funding rounds of Zim Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2021Grant––
–
Jan 2013$8.2MSeries A––
Valuation history

1 investors in total: 1 institutional.

Investors in Zim Labs

Zim Labs has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ashmore.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Investment management services are provided by Ashmore globally.
1992ashmoregroup.comLondon, United Kingdom
Premium access

Investor details for Zim Labs

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Zim Laboratories Limited. (Zim Labs)

Zim Laboratories Limited. is the primary company behind Zim Labs. The board of Zim Laboratories Limited. currently have 8 directors; the longest-serving is Anwar Siraj Daud, appointed in 2009. 14 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Anwar Siraj Daud
DIN 00023529
Managing Director01 Apr 200917 yrs 7 moZim Laboratories Limited.
Zulfiquar Murtaza Kamal
DIN 01786763
Whole-time director19 Oct 201214 yrs 1 moZim Laboratories Limited.
Prakash Pralahadrao Sapkal
DIN 02007385
Whole-time director22 Nov 201312 yrs 11 moZim Laboratories Limited.
Niraj Pukhraj Dhadiwal
DIN 02007428
Whole-time director22 Nov 201312 yrs 11 moZim Laboratories Limited.
Kavita Loya
DIN 07943519
Director21 Sep 20179 yrs 1 moZim Laboratories Limited.
Padmakar Shrinivas Joshi
DIN 07944709
Director21 Sep 20179 yrs 1 moZim Laboratories Limited.
Kamlesh Bajirao Shende
DIN 09537666
Director01 Apr 20224 yrs 7 moZim Laboratories Limited.
Ashok Bhatia
DIN 02090239
Director01 Apr 20251 yr 7 moZim Laboratories Limited.

People of Zim Labs

14 people are tracked at Zim Labs (2 in leadership, 9 in board & advisors, 3 in team); the tracked headcount is 577.

NameRoleGroup
Shyam Mohan Patro
CFO, Accounts & FinanceLeadership
Pradeep Kataria
Senior Vice PresidentLeadership
Chandrashekhar Mainde
DirectorBoard & advisors
Gautam Saigal
DirectorBoard & advisors
DirectorBoard & advisors
DirectorBoard & advisors
DirectorBoard & advisors
DirectorBoard & advisors
DirectorBoard & advisors
DirectorBoard & advisors
Kakasaheb Mahadik
DirectorBoard & advisors
DEEPENDRA MAHULE
EA to MDTeam
Bhushan Shukla
ManagerTeam
Chairman & MDTeam
Premium access

Complete people profiles for Zim Labs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Zim Labs

Zim Labs is a publicly listed company on the NSE with ticker symbol ZIMLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Nov 2022
  • Listed onNSE: ZIMLAB
  • Listed entityZim Laboratories Ltd.
  • Exchange sectorHealth technology
  • ISININE518E01015
  • Share price₹146.78 (+0.01% on the day) · 2026-10-14
  • Market capitalisation₹789 Cr
  • Price to earnings177.9
  • EPS (diluted, trailing year)₹0.83
  • Volume (last session)68,587

Financials of Zim Labs

Exchange-reported figures of Zim Laboratories Limited., the listed company behind Zim Labs (NSE: ZIMLAB).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹374 Cr
-1.2% YoY
EBITDA
₹30.01 Cr
-31.4% YoY
Profit After Tax
₹4.35 Cr
-63.5% YoY
Net Worth
₹296 Cr
+17.4% YoY
Total Assets
₹423 Cr
+14.2% YoY
Total Debt
₹127 Cr
+7.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue374379367399333307278
Revenue growth-1.2%+3.2%-7.8%+19.5%+8.5%+10.6%-
EBITDA30.0143.7241.3351.9940.9734.5822.62
EBITDA margin+8.0%+11.5%+11.3%+13.1%+12.3%+11.3%+8.1%
Profit before tax8.2118.0023.6435.3521.0310.230.08
Net profit4.3511.9217.2624.4314.5411.033.31
Net profit margin+1.2%+3.1%+4.7%+6.1%+4.4%+3.6%+1.2%
EPS (β‚Ή)1.092.503.545.018.964.512.04
Balance sheet
Total assets423370351262229243244
Net worth296252239200176161154
Total debt12711811262.1653.4482.3289.85
Cash & bank43.412.4910.467.524.978.353.95
Net working capital170140141117100110101
Cash flow
Cash from operations49.5341.1516.2837.5249.2131.8521.92
Cash from investing(54.54)(39.70)(72.63)(35.06)(14.21)(5.95)(18.44)
Cash from financing28.19(9.10)59.530.55(32.97)(25.97)(2.51)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10594.1810510988.7171.7610996.33
Revenue growth (YoY)+18.9%+31.2%-3.2%+12.8%-3.7%-12.3%--
Other income2.300.996.161.702.041.481.711.75
EBITDA5.432.457.1912.815.754.2614.5911.56
EBITDA margin+5.1%+2.6%+6.8%+11.8%+6.5%+5.9%+13.4%+12.0%
Depreciation6.535.375.105.034.984.865.294.88
Interest3.943.643.313.433.163.302.912.73
Profit before tax(2.74)(5.57)4.946.05(0.35)(2.42)8.105.70
Tax(0.69)(1.56)1.201.650.08(0.55)3.221.71
Net profit(2.05)(4.01)3.744.40(0.43)(1.87)4.883.99
EPS (β‚Ή)(0.38)(0.75)0.760.90(0.09)(0.38)1.010.82
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue370376365397329304274
Revenue growth-1.4%+2.8%-7.8%+20.4%+8.5%+10.7%-
EBITDA29.5743.2740.0951.2037.9331.6419.79
EBITDA margin+8.0%+11.5%+11.0%+12.9%+11.5%+10.4%+7.2%
Profit before tax8.3917.6123.0335.9219.298.59(1.47)
Net profit4.3911.6616.7625.0113.019.011.76
Net profit margin+1.2%+3.1%+4.6%+6.3%+4.0%+3.0%+0.6%
EPS (β‚Ή)1.112.413.445.138.013.461.08
Balance sheet
Total assets413362344256224239242
Net worth286245232194170157152
Total debt12711811262.1653.4482.3289.85
Cash & bank37.000.820.752.212.097.862.83
Net working capital15112612910589.0710295.65
Cash flow
Cash from operations47.6650.6011.4735.2347.0331.9021.29
Cash from investing(57.41)(41.31)(71.94)(35.21)(14.42)(5.70)(18.82)
Cash from financing28.19(9.10)59.530.55(32.97)(25.96)(2.16)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10493.0510310888.3971.4310995.40
Revenue growth (YoY)+17.9%+30.3%-5.2%+13.0%-1.5%-12.9%--
Other income2.290.996.161.712.041.481.551.76
Total expenses99.1090.6496.2895.3182.2267.0993.2883.63
EBITDA5.122.416.5712.506.174.3415.2411.77
EBITDA margin+4.9%+2.6%+6.4%+11.6%+7.0%+6.1%+14.0%+12.3%
Depreciation6.265.174.904.854.834.795.234.77
Interest3.943.643.313.433.163.302.912.73
Profit before tax(2.79)(5.41)4.525.930.22(2.27)8.656.03
Tax(0.65)(1.55)1.241.670.11(0.59)3.231.68

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10594.1810510988.7171.7610996.33
Revenue growth (YoY)+18.9%+31.2%-3.2%+12.8%-3.7%-12.3%--
Other income2.300.996.161.702.041.481.711.75
EBITDA5.432.457.1912.815.754.2614.5911.56
EBITDA margin+5.1%+2.6%+6.8%+11.8%+6.5%+5.9%+13.4%+12.0%
Depreciation6.535.375.105.034.984.865.294.88
Interest3.943.643.313.433.163.302.912.73
Profit before tax(2.74)(5.57)4.946.05(0.35)(2.42)8.105.70
Tax(0.69)(1.56)1.201.650.08(0.55)3.221.71
Net profit(2.05)(4.01)3.744.40(0.43)(1.87)4.883.99
EPS (β‚Ή)(0.38)(0.75)0.760.90(0.09)(0.38)1.010.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue374379367399333307278
Revenue growth-1.2%+3.2%-7.8%+19.5%+8.5%+10.6%-
Other income11.385.785.186.414.402.344.52
Total expenses344335326347292273255
Employee cost63.9060.7653.3449.3240.0735.7635.35
EBITDA30.0143.7241.3351.9940.9734.5822.62
EBITDA margin+8.0%+11.5%+11.3%+13.1%+12.3%+11.3%+8.1%
Depreciation19.9820.1115.9517.4716.0315.7914.41
Interest13.2011.396.925.588.3110.9012.65
Profit before tax8.2118.0023.6435.3521.0310.230.08
Tax2.375.846.3910.926.492.91(3.22)
Net profit4.3511.9217.2624.4314.5411.033.31
Net profit margin+1.2%+3.1%+4.7%+6.1%+4.4%+3.6%+1.2%
EPS (β‚Ή)1.092.503.545.018.964.512.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.5048.7348.7348.7316.2416.2416.18
Reserves & surplus240202190152159145138
Shareholders' funds (net worth)296252239200176161154
Minority interest0.000.000.000.000.000.000.00
Secured loans12011210659.5751.3181.0789.44
Unsecured loans6.085.635.422.592.131.250.41
Total debt12711811262.1653.4482.3289.85
Total liabilities423370351262229243244
Assets
Gross block290275267199180165159
Net block162164161109106107116
Capital work in progress95.5370.4642.2826.9911.7510.689.62
Investments0.050.050.050.050.050.050.05
Inventories93.7786.4781.2653.7175.2854.3556.39
Sundry debtors10910710095.2589.5272.2567.93
Cash & bank balances43.412.4910.467.524.978.353.95
Loans & advances29.5835.4235.7634.4842.3656.8153.76
Total current assets276231228191212192182
Total current liabilities10690.9386.2174.2611281.7181.01
Net working capital170140141117100110101
Total assets423370351262229243244
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.959.606.423.421.391.460.50
Net cash from operating activities49.5341.1516.2837.5249.2131.8521.92
Net cash from investing activities(54.54)(39.70)(72.63)(35.06)(14.21)(5.95)(18.44)
Net cash from financing activities28.19(9.10)59.530.55(32.97)(25.97)(2.51)
Net change in cash23.18(7.65)3.183.002.03(0.07)0.96
Closing cash43.412.4910.467.524.978.353.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-1.2%+3.2%-7.8%+19.5%+8.5%+10.6%-
EBITDA growth-31.4%+5.8%-20.5%+26.9%+18.5%+52.9%-
PBT growth-54.4%-23.9%-33.1%+68.1%+105.6%--99.6%
Net income growth-63.5%-30.9%-29.4%+68.0%+31.8%+233.2%-
Revenue CAGR (3Y)-2.1%+4.4%+6.1%+12.8%-0.2%+4.0%+5.7%
EBITDA CAGR (3Y)-16.7%+2.2%+6.1%+32.0%-0.9%-0.2%-10.4%
Profitability & leverage
Net income margin+1.6%+3.2%+4.7%+6.1%+4.4%+2.4%+1.2%
Return on capital employed+4.8%+8.2%+10.0%+16.7%+12.4%+10.8%+5.4%
Return on net worth+1.6%+5.0%+7.9%+13.0%+8.7%+7.0%+2.2%
Debt / equity0.450.470.400.310.400.550.55
Long-term debt / equity0.220.230.200.190.210.240.25
Interest cover131.6148.2427.2716.1633.3258.01153.89
Efficiency & per share
Fixed asset turnover1.331.401.582.101.931.891.88
Inventory turnover4.154.525.446.185.145.554.98
Debtors turnover3.473.663.764.314.124.383.45
EPS (β‚Ή)1.092.503.545.018.964.512.04
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)54.9051.4949.0041.12108.1898.9795.06
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10493.0510310888.3971.4310995.40
Revenue growth (YoY)+17.9%+30.3%-5.2%+13.0%-1.5%-12.9%--
Other income2.290.996.161.712.041.481.551.76
Total expenses99.1090.6496.2895.3182.2267.0993.2883.63
EBITDA5.122.416.5712.506.174.3415.2411.77
EBITDA margin+4.9%+2.6%+6.4%+11.6%+7.0%+6.1%+14.0%+12.3%
Depreciation6.265.174.904.854.834.795.234.77
Interest3.943.643.313.433.163.302.912.73
Profit before tax(2.79)(5.41)4.525.930.22(2.27)8.656.03
Tax(0.65)(1.55)1.241.670.11(0.59)3.231.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue370376365397329304274
Revenue growth-1.4%+2.8%-7.8%+20.4%+8.5%+10.7%-
Other income11.395.624.696.434.512.454.66
Total expenses341332325345292272255
Employee cost60.1056.4150.8146.4738.6334.4834.58
EBITDA29.5743.2740.0951.2037.9331.6419.79
EBITDA margin+8.0%+11.5%+11.0%+12.9%+11.5%+10.4%+7.2%
Depreciation19.3719.8914.8316.1314.8414.6113.27
Interest13.2011.396.925.588.3110.8912.65
Profit before tax8.3917.6123.0335.9219.298.59(1.47)
Tax2.445.876.2810.916.282.97(3.22)
Net profit4.3911.6616.7625.0113.019.011.76
Net profit margin+1.2%+3.1%+4.6%+6.3%+4.0%+3.0%+0.6%
EPS (β‚Ή)1.112.413.445.138.013.461.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.5048.7348.7348.7316.2416.2416.18
Reserves & surplus230194183145154141136
Shareholders' funds (net worth)286245232194170157152
Secured loans12011210659.5751.3181.0789.44
Unsecured loans6.085.635.422.592.131.250.41
Total debt12711811262.1653.4482.3289.85
Total liabilities413362344256224239242
Assets
Gross block281268260192174160153
Net block160164160107103103111
Capital work in progress89.4065.6740.2526.2611.4210.469.62
Investments17.6613.048.238.188.188.088.08
Inventories93.7786.4781.2653.7175.2854.3556.39
Sundry debtors92.2893.6810088.3680.8963.9563.34
Cash & bank balances37.000.820.752.212.097.862.83
Loans & advances29.3835.3835.6134.3742.3356.8153.73
Total current assets252216218179201183176
Total current liabilities10290.7788.6873.7211280.9180.64
Net working capital15112612910589.0710295.65
Total assets413362344256224239242
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.360.171.110.540.900.670.36
Net cash from operating activities47.6650.6011.4735.2347.0331.9021.29
Net cash from investing activities(57.41)(41.31)(71.94)(35.21)(14.42)(5.70)(18.82)
Net cash from financing activities28.19(9.10)59.530.55(32.97)(25.96)(2.16)
Net change in cash18.430.19(0.94)0.57(0.36)0.230.31
Closing cash37.000.820.752.212.097.862.83
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-1.4%+2.8%-7.8%+20.4%+8.5%+10.7%-
EBITDA growth-31.7%+7.9%-21.7%+35.0%+19.9%+59.9%-
PBT growth-52.4%-23.5%-35.9%+86.2%+124.6%+9998.0%-
Net income growth-62.4%-30.4%-33.0%+92.2%+44.4%+411.9%-
Revenue CAGR (3Y)-2.2%+4.5%+6.4%+13.1%-0.2%+3.8%+5.3%
EBITDA CAGR (3Y)-16.7%+4.5%+8.2%+37.3%-3.7%-2.3%-14.4%
Profitability & leverage
Net income margin+1.6%+3.1%+4.6%+6.3%+4.0%+1.9%+0.6%
Return on capital employed+4.9%+8.2%+10.0%+17.3%+11.9%+10.2%+4.7%
Return on net worth+1.7%+4.9%+7.9%+13.7%+8.0%+5.8%+1.2%
Debt / equity0.460.480.410.320.410.560.55
Long-term debt / equity0.160.170.150.160.210.160.20
Interest cover129.4148.7227.4015.9135.9963.95194.02
Efficiency & per share
Fixed asset turnover1.351.421.622.171.981.941.94
Inventory turnover4.114.485.426.155.085.484.92
Debtors turnover3.983.883.884.694.554.773.57
EPS (β‚Ή)1.112.413.445.138.013.461.08
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)53.0749.9047.6039.85104.7396.6993.79

Timeline of Zim Labs

4 dated milestones of Zim Labs across 33 years, from founding to its latest funding, stage changes and deals.

  1. Founded Zim Labs is founded.
  2. Funding First funding round of $8.2M.
  3. Funding Latest funding round, Grant,.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Zim Labs

Zim Labs has 2 listed competitors in our database, 1 of them funded. They include Inventia Healthcare and Halewood Laboratories.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
inventiahealthcare.com1985Mumbai, India$42.49M980
Oral solid drug delivery systems are manufactured and developed.
halewoodlabs.com1984Ahmedabad, India348
Provides contract manufacturing services for food, pharmaceuticals, and related products globally.
Premium access

Detailed competitors of Zim Labs

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Zim Labs

The website of Zim Labs (zimlab.in) receives about 12.1K visits a month and ranks #1,856,720 among all websites worldwide, #2,538 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    12.1K
  • Unique visitors
    5.5K

    per month

  • Global rank
    #1,856,720

    among all websites

  • Category rank
    #2,538

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Zim Labs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
naturalremedy.com
100%
42.1K#964,146View details
ondrugdelivery.com
100%
#833,579View details
cooperpharma.com
95%
17.9K#1,398,892View details
akums.in
91%
25.5K#1,037,095View details
bionova.co.in
84%
13.3K#2,213,654View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 11 similar websites and full traffic analytics for Zim Labs

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Zim Labs (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Zim Labs

Premium access

Complete news archive for Zim Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Zim Labs

Zim Labs was founded in 1989 and raised its 1st funding round 24 years after it was founded.

Zim Labs is headquartered in Nagpur, India. It is registered at Nagpur, Maharashtra, India.

Zim Labs is a funded company, having raised a total of $8.2M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.2M, raised on Jan 2013.

Zim Labs has 577 employees.

The primary company behind Zim Labs, Zim Laboratories Limited., reported revenue of β‚Ή386 Cr for FY 2026, down 1% year on year.

Zim Labs was founded in 1989 and is based in Nagpur, India, within the pharmaceutical sector. Various solid and semisolid dosage forms, such as granules, pellets with sustained, modified, or extended release, taste-masked powders, suspensions, tablets, capsules, and oral thin films, are developed and manufactured. Services provided include drug release modifications, solubility enhancement, and taste masking for pharmaceutical applications.

Zim Labs's top competitors include Inventia Healthcare and Halewood Laboratories.

Zim Labs offers Oral Thin Films, Pre-Formulation Intermediates, and Finished Formulations.

Yes, Zim Labs is publicly traded on NSE under the ticker symbol ZIMLAB.

Zim Labs has 1 investor. Key investors include Ashmore.

Zim Labs operates through Zim Laboratories Limited..

The legal entities of Zim Labs currently have 10 directors, including Zulfiquar Murtaza Kamal, Prakash Pralahadrao Sapkal, Niraj Pukhraj Dhadiwal and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available